Amarnath Yatra bus attack: 8 LeT men named in charge sheet | WeForNews | Latest News, Blogs Amarnath Yatra bus attack: 8 LeT men named in charge sheet – WeForNews | Latest News, Blogs
Connect with us

Health

Amarnath Yatra bus attack: 8 LeT men named in charge sheet

Published

on

amarnath terror attack2'

Srinagar, Jan 29: Jammu and Kashmir Police on Monday lodged a charge sheet against terror outfit Lashkar-e-Taiba (LeT) and eight persons accused in the Amarnath Yatra bus attack in July 2017 in which eight pilgrims were killed.

“The charge sheet of about 1,500 pages pertaining to the yatra bus attack on July 10, 2017 is against the LeT and eight accused…,” a police statement said.

“A special investigation team (SIT) was formed which filed a comprehensive charge sheet against eight accused persons before Sessions Court Anantnag and Chief Judicial Magistrate (Juvenile Court) Anantnag”.

The statement said the main accused in the case, Abu Ismail, a Pakistani national of the LeT terror group was killed in a gunfight with the security forces on September 14, 2017, while his other two Pakistani associates were also killed on December 12.

Disaster

Russia 1st nation to finish human trials for Covid-19 vaccine

There are at least 21 vaccines currently under key trials, according to the World Health Organisation (WHO).

Published

on

Covid 19 Vaccine

Moscow, July 12 : Russia has become the first nation to complete clinical trials of Covid-19 vaccine on humans, and the results have proven the medication’s effectiveness, the media reported on Sunday.

Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine have been completed at the university and they will be discharged soon.

“The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20,” Smolyarchuk was quoted as saying in the report.

There was, however, no further information on when this vaccine would enter commercial production stage.

Russia had allowed clinical trials of two forms of a potential Covid-19 vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology on June 18.

The first vaccine, in the form of a solution for intramuscular administration, was carried out at the Burdenko Military Hospital.

Another vaccine, in the form of a powder for the preparation of a solution for intramuscular administration, was carried out at Sechenov First Moscow State Medical University.

The first stage of research on the vaccine at Sechenov University involved a group of 18 volunteers and the second group involved 20 volunteers.

After vaccination, all volunteers were expected to remain in isolation in a hospital for 28 days.

Earlier, results of the COVID-19 vaccine tests performed on a group of volunteers in Russia showed that they were developing immunity to the coronavirus.

“The data obtained by the Gamalei National Research Center for Epidemiology and Microbiology, proves that volunteers of the first and second groups are forming an immune response after injections of the vaccine against the coronavirus,” according to an earlier statement from the Russian Defense Ministry.

Russia has reported 719,449 cases and 11,188 deaths to date.

There are at least 21 vaccines currently under key trials, according to the World Health Organisation (WHO).

The overall number of global COVID-19 cases was nearing 12.7 million, while the deaths have increased to more than 564,000, according to Johns Hopkins University in the US.

As of Sunday morning, the total number of cases stood at 12,681,472, while the fatalities rose to 564,420.

The US accounted for the world’s highest number of infections and fatalities at 3,245,158 and 134,764. Brazil came in the second place with 1,839,850 infections and 71,469 deaths.

Continue Reading

Health

Researchers design reusable silicone rubber face mask with N95 filter

“We also wanted to maximise the reusability of the system, and we wanted systems that could be sterilized in many different ways,” Traverso added.

Published

on

N-95 mask

New York, July 11 : In fight against novel coronavirus, the researchers have developed a reusable silicone rubber face mask with an N95 filter, which they believe could stop viral particles.

According to the study, published in the British Medical Journal Open, the new masks were designed to be easily sterilized and used many times.

The new mask is made of durable silicone rubber and can be manufactured using injection moulding, which is widely used in factories around the world. It requires much less N95 material than a traditional N95 mask.

“One of the key things we recognized early on was that in order to help meet the demand, we needed to really restrict ourselves to methods that could scale,” said study researcher Giovanni Traverso from Massachusetts Institute of Technology (MIT) in the US.

“We also wanted to maximise the reusability of the system, and we wanted systems that could be sterilized in many different ways,” Traverso added.

The researchers decide on silicone rubber — the material that goes into silicone baking sheets, among other products — because it is so durable.

Liquid silicone rubber can be easily moulded into any shape using injection moulding, a highly automated process that generates products rapidly. The masks are based on the shape of the 3M 1860 style of N95 masks, the type normally used at Brigham and Women”s Hospital.

The researchers tested several different sterilization methods on the silicone masks, including running them through an autoclave (steam sterilizer), putting them in an oven, and soaking them in bleach and in isopropyl alcohol.

They found that after sterilization, the silicone material was undamaged.To test the comfort and fit of the masks, the researchers recruited about 20 health care workers from the emergency department and an oncology clinic at Brigham and Women”s Hospital.

All 20 participants passed the fit test, and they reported that they were able to successfully insert and remove the N95 filter. When asked their preference between the new mask, a typical N95 mask, and a standard surgical mask, most either said they had no preference or preferred the new silicone mask, the researchers said.

They also gave the new mask high ratings for fit and breathability.The researchers are now working on a second version of the mask, which they hope to make more comfortable and durable. They also plan to do additional lab tests measuring the masks” ability to filter viral particles.

Continue Reading

Disaster

Remdesivir linked to reduced death risk in severe Covid-19 patients

The mortality rate for patients treated with remdesivir in the analysis was 7.6 per cent at Day 14 compared with 12.5 per cent among patients not taking remdesivir.

Published

on

remdesivir antiviral drug

New York, July 11 : New data revealed by Gilead Sciences has shown that its antiviral drug remdesivir reduces death risk of severe Covid-19 patients by as much as 62 per cent when compared with standard care alone.

This is an important finding that requires confirmation in prospective clinical trials, Gilead said on Friday about the results presented at the virtual COVID-19 conference as part of the 23rd International AIDS Conference.

The analysis included 312 patients treated in the Phase-3 SIMPLE-Severe study and a separate real-world retrospective cohort of 818 patients with similar baseline characteristics and disease severity who received standard of care treatment in the same time period as the SIMPLE-Severe study.

Patients were primarily located in North America (92 per cent, remdesivir cohort vs. 91 per cent, standard-of-care cohort), Europe (5 per cent vs. 7 per cent) and Asia (3 per cent vs. 2 per cent).

The analysis demonstrated that remdesivir treatment was associated with significantly improved clinical recovery and a 62 percent reduction in the risk of mortality compared to standard of care.

Findings from the comparative analysis showed that 74.4 per cent of remdesivir-treated patients recovered by Day 14 versus 59 per cent of patients receiving standard of care.

The mortality rate for patients treated with remdesivir in the analysis was 7.6 per cent at Day 14 compared with 12.5 per cent among patients not taking remdesivir.

“This comparative analysis provides valuable additional information regarding the benefit of remdesivir compared with standard of care alone,” Susan Olender of Columbia University Irving Medical Center said in a statement.

“While not as vigorous as a randomized controlled trial, this analysis importantly draws from a real-world setting and serves as an important adjunct to clinical trial data, adding to our collective understanding of this virus and reflecting the extraordinary pace of the ongoing pandemic.”

The results of this comparative analysis add to the previously presented National Institute of Allergy and Infectious Disease (NIAID) randomized, double-blind, placebo-controlled study in hospitalized patients with COVID-19, which showed that remdesivir shortened time to recovery by an average of four days as compared to placebo — 11 vs. 15 days.

In the NIAID study, patients taking remdesivir trended toward lower mortality compared with those in the placebo group, but this result did not reach statistical significance –7.1 percent vs. 11.9 per cent.

Due to the current public health emergency, the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization for remdesivir for the treatment of hospitalised patients with severe Covid-19.

“These data presented at the Virtual COVID-19 Conference shed additional light on the use of remdesivir in specific patient populations, including those that may be susceptible to higher rates of COVID-19 infection, as well as others that are particularly vulnerable, including children and pregnant and postpartum women,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

Continue Reading
Advertisement

Most Popular